Home Alzheimer’s Disease Improved Survival with Adjuvant Chemoendocrine Therapy in HR+/ERBB2+ Tumors

Improved Survival with Adjuvant Chemoendocrine Therapy in HR+/ERBB2+ Tumors

In a research letter published in JAMA Network Open, researchers suggested that there is a correlation between improved survival and adjuvant chemoendocrine therapy, specifically for hormone receptor (HR)-positive, ERBB2 (formerly HER2/neu)-positive tumors 8 mm to 10 mm.

According to the researchers, recurrence rates for patients with HR-positive, ERBB2-positive tumors range from less than 5% up to 25% at 5 years, with or without adjuvant treatments. With randomized trial data on the role of chemotherapy for small tumors currently lacking in this disease space, the cutoff size at which chemotherapy should be omitted remains uncertain.

While relevant prospective clinical trials continue to accrue data, the researchers indicated that this data could help clinicians in decision-making regarding adjuvant systemic therapy for patients with small HR-positive, ERBB2-positive breast…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments